Our achievements would not be possible without the outstanding team that make up Shield Therapeutics’ staff, Senior Executive Team and Board of Directors.
Chief Executive Officer
Greg Madison is a seasoned executive who brings strong operating experience and a track record of success leading small to medium-sized organizations. Prior to joining Shield, he was Chief Executive Officer at Melt Pharmaceuticals in Boston, MA, a company developing a sublingual formulation of midazolam and ketamine, providing needle and opioid-free procedural sedation and analgesia. Prior to Melt Pharmaceuticals, he was Chief Executive Officer of Keryx Biopharmaceuticals from 2015 to 2018, where he led the transformation of the organization from development stage to commercial stage focused on Auryxia, an oral product for the treatment of hyperphosphatemia and iron deficiency anemia, and ultimately leading to a merger with Akebia Therapeutics. In 2013 and 2014, he was Chief Commercial Officer at AMAG Pharmaceuticals where he was closely involved with Feraheme, a leading intravenous product for the treatment of iron deficiency. From 2000–2012, Greg was at Genzyme Corporation, ultimately serving as Vice President and General Manager of its Nephrology Division, where he led a division that had revenues in excess of $1 billion, led by the world’s leading phosphate binder, Renvela. Greg began his career as a sales representative for Janssen Pharmaceuticals, a division of Johnson and Johnson.
Chief Financial Officer
Hans-Peter is Chief Financial Officer at Shield and brings extensive international experience to the senior team. Hans-Peter studied at the University of Zurich and Cleveland State University, Ohio, and is a US Certified Public Accountant (CPA). Hans-Peter began his career in 1991 in public practice with Deloitte in Cleveland, Ohio, before joining Ernst & Young (Switzerland) where he became a partner in 2001 and moved back to the Cleveland office in 2003 as an audit partner. In 2006 he joined Crowe Horwath (now Crowe) as an audit partner within the eighth largest global accounting network. In 2011 Hans-Peter left public practice to become Head of Group Accounting at COFRA Group, a privately held Swiss conglomerate with activities in retail, real estate and investment, employing over 50,000 people worldwide. In 2017, he was appointed as Chief Financial Officer at Vicarius Pharma, a start-up company offering research-driven pharma and biotech companies a platform to build a dedicated European commercial organization to market and sell their assets through long-term license and partnership agreements.
Chief Commercial Officer
Andy joins Shield from Agenus Inc (“Agenus”), where he was Chief Commercial and Medical/Clinical Officer. At Agenus he was responsible for leading the commercial, medical affairs and clinical operations functions and was leading the company as it prepared for multiple immuno-oncology product launches. Prior to Agenus, Andy was Senior Vice President of a commercial division at Syneos Health where he led a global team that launched nine products across several therapeutic areas during his tenure at the company. Before that, he was Chief Commercial Officer at Ocular Therapeutix where he helped the organisation in preparing the company for its first pharmaceutical launch. Andy has also held senior leadership roles across marketing, sales, and operations functions at Sunovion, Dyax, NitroMed and Forest Pharmaceuticals. Andy has a Bachelor of Science in Consumer Studies from the University of Vermont and did post-graduate work in Finance and Marketing at Bentley University's McCallum Graduate School of Business.
General Counsel and Company Secretary
Lucy Huntington-Bailey has been the Group’s Legal Advisor since August 2015 and was an integral member of the team working towards the successful admission of Shield Therapeutics to the AIM market in early 2016. Having worked previously at a boutique corporate law firm and prior to that an international US law firm in Singapore, Lucy brings to Shield a wealth of experience in the oil and gas sector as well as the pharmaceutical industry. Lucy was promoted to Senior In-House Counsel in December 2016, General Counsel in 2018 and is responsible for the management of the Group’s legal team and all legal advice and services. Lucy was appointed by the Board of Directors to the role of Company Secretary in September 2017. Lucy is admitted as a Solicitor of the Senior Courts of England and Wales.
VP Commercial Operations
David joined Shield Therapeutics in 2011 as Director of Manufacturing with the primary objective of creating a robust manufacturing process with multiple CMOs for the development and commercialization of our lead medicine, ACCRUFeR®. During his tenure David has also had a central role in developing and managing the Company’s intellectual property, whilst more recently adding responsibility for the development of commercial alliances. Prior to joining Shield, David gained over 18 years of experience in chemical and pharmaceutical development at GlaxoSmithKline (GSK), where he led several successful projects and teams including the manufacturing elements of the successful Promacta® and Relovair® developments.
Dr Jackie Mitchell
VP Quality, Clinical and Regulatory Affairs
Jackie has over 20 years’ experience in regulatory affairs. She holds an MA in biochemistry from Lady Margaret Hall in Oxford, where she also obtained a doctorate in immunology and molecular biology. Following completion of her academic studies, Jackie spent a number of years working as a research scientist, including a period at Johns Hopkins School of Medicine in Baltimore, USA. Since moving into the pharmaceutical industry, Jackie has worked in regulatory affairs for large, medium and small pharmaceutical companies, including Boehringer Ingelheim, Abbott and Archimedes. She has been involved in a broad range of global, EU and national applications across many therapeutic areas and has led several major regulatory projects, including successful MAA and NDA submissions, including the NCEs Kaletra and Humira. Jackie has run the Group’s regulatory activities since 2012.
Hans Peter Hasler
Hans Peter joined the Board of Shield Therapeutics plc in July 2018. Mr. Hasler was the Chief Executive Officer of Vicarius Pharma AG, a privately held European biopharma company until 2020. His prior experiences include Elan Corporation, Dublin, where he was Chief Operating Officer, and Biogen Inc., Boston, where his positions included Chief Operating Officer, and EVP, Head of Global Neurology and International. Previously, Mr. Hasler was at Wyeth Pharmaceuticals, Radnor/PA, as Senior Vice President, Chief Marketing Officer and beforehand Managing Director of Wyeth Group Germany, Münster.
Hans Peter Hasler is Chairman of the Board of HBM Healthcare Investments AG in Switzerland (SIX), Chairman of the Board of Shield Therapeutics, London (AIM), and a Director of Minerva Neurosciences in Boston (Nasdaq) and Gain Therapeutics, Bethesda (Nasdaq). He holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business Economy SIB, Zurich.
Hans Peter is a member of the Remuneration Committee and chair of the Nomination Committee.
Chief Executive Officer
Greg Madison is a seasoned executive who brings strong operating experience and a track record of success leading small to medium size organizations. Prior to joining Shield, he was Chief Executive Officer at Melt Pharmaceuticals in Boston, MA, a company developing a sublingual formulation of midazolam and ketamine, providing needle and opioid-free procedural sedation and analgesia. Prior to Melt Pharmaceuticals, he was Chief Executive Officer of Keryx Biopharmaceuticals from 2015 to 2018, where he led the transformation of the organization from development stage to commercial stage focused on Auryxia, an oral product for the treatment of hyperphosphatemia and iron deficiency anaemia, and ultimately leading to a merger with Akebia Therapeutics. In 2013 and 2014, he was Chief Commercial Officer at AMAG Pharmaceuticals where he was closely involved with Feraheme, a leading intravenous product for the treatment of iron deficiency. From 2000-2012, Greg was at Genzyme Corporation, ultimately serving as Vice President and General Manager of its Nephrology Division, where he led a division that had revenues in excess of $1 billion dollars, led by the world’s leading phosphate binder, Renvela. Greg began his career as a sales representative for Janssen Pharmaceuticals, a division of Johnson and Johnson.
Peter has over 25 years’ experience in international M&A deals, company turnarounds, licensing transactions and financing activities including IPOs with particular experience in chemical and healthcare industries. He is currently CEO/CFO of Apeiron Biologics AG. Peter was CFO/CBO of Medigene AG between 2012 and 2016 and was fundamental in the turnaround process by out licensing marketed and legacy products and enhancing shareholder value with a new large international investor base. Prior to that he was CFO of Wilex AG, having orchestrated its IPO in 2006. Peter read Business Management, Banking, Marketing and Controlling in London, St. Gallen and Munich, and has a certificate in Business Studies from the University of London.
Peter is the chair of the Audit Committee and a member of the Nomination Committee.
Dr Christian Schweiger, MD, PhD
Christian is one of the founders of Shield Therapeutics where he was responsible for the discovery and initial clinical development programs until 2012. He is an entrepreneurial senior medical affair, and clinical development executive with vast experience in both large and small pharmaceutical companies. He serves in various boards and will focus on Shield Therapeutics' medical, and scientific strategy. He is Managing Director of his own boutique consultancy business TACHRIS AG in Switzerland providing clinical, medical, medical marketing and strategic management consultancy services including pharmaceutical asset evaluation.
Dr Schweiger is also Lecturing Professor in Pharmaceutical Medicine at the University of Essen and actively working with different international patient and professional associations.
Christian is a member of the Remuneration and Nomination Committees.
Fabiana is currently Senior Vice President, Chief Compliance Officer at Aimmune Therapeutics based in San Francisco, California (a Nestlé Health Science Corporation since October 2020). She brings to Shield extensive experience in compliance having started and implemented compliance programs at several major pharmaceutical companies including Merck, Sharp & Dohme, Bristol-Myers Squibb Company, Mylan Laboratories and Elan Pharmaceuticals. Fabiana was also a Non-Executive Director at ArthroCare Corporation, a publicly traded company in the medical device sector prior to its acquisition by Smith & Nephew in 2014. Fabiana holds a Master's in Law from the University of California, a Doctor in Law and a Bachelor in Law from the Universidad de Buenos Aires and is the recipient of several international recognitions and has been published extensively in areas of leadership and compliance.
Fabiana is a member of the Audit and Nomination Committees.
Anders brings over 30 years of global pharmaceutical/biotech experience. He is currently Executive Vice President and Chief Commercial Officer at Banner Life Sciences where he is planning and executing a US launch of a novel treatment of Multiple Sclerosis. He has previously held senior commercial and general management roles in AstraZeneca, Biogen, Orexo AB, where he was President and CEO, EMD Serono, and Santhera Pharmaceuticals. Anders holds an MSc in Pharmacy from Uppsala University and a Diploma in Business Administration from IHM, Stockholm.
Anders is chair of the Remuneration Committee and member of the Nomination Committee.